Abstract
Background: COVID-19 is an infectious disease caused by SARS-CoV-2 and can lead to acute respiratory distress.
Objective: We aimed to investigate the association between COVID-19 severity and serum apelin- 17 and inflammatory mediator levels.
Methods: This cross-sectional study was conducted on patients with COVID-19. COVID-19 infection was confirmed by the RT-PCR test. The patients' data were extracted from their records. Venous blood samples were obtained from the patients to investigate the serum levels of apelin-17 and inflammatory mediators.
Results: Eighty-six COVID-19 patients were studied. The mean age of the participants was 55.56±14.88, and 43 (50 %) were male. Clinical symptoms were dyspnea 77.6 %, fever 52.3 %, cough 48.8 %, gastrointestinal symptoms 15.1 %, and chest pain 7 %. The overall mortality rate was 7 %. No significant relationship was found between serum apelin-17 levels and COVID-19 severity (P= 0.48). However, there was a significant and direct relationship between COVID-19 severity and serum levels of CRP (P= 0.038) and D-dimer (P= 0.029).
Conclusion: Serum apelin-17 levels were higher in recovered patients than those who died (4.90 vs. 3.19). Moreover, serum apelin-17 levels were higher in the patients admitted to the general ward than those admitted to the ICU (5.15 vs. 3.98). The difference was not statistically significant. However, there was a significant and direct relationship between serum apelin-17 levels and lymphocyte count (P= 0.022). Moreover, there was a significant and inverse relationship between lymphocyte count and COVID-19 severity (P= 0.004). Therefore, it can be interpreted that COVID-19 severity may decrease with an increase in serum apelin-17 levels. Therefore, to prove this hypothesis, a study with larger sample size is recommended.
Keywords: Severity, COVID-19, Apelin, D-dimer, C-reactive protein, pneumonia.
Graphical Abstract
[http://dx.doi.org/10.1101/2020.01.22.914952]
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[http://dx.doi.org/10.1002/jmv.25757] [PMID: 32162702]
[http://dx.doi.org/10.1515/cclm-2020-0198] [PMID: 32119647]
[http://dx.doi.org/10.1006/bbrc.1998.9489] [PMID: 9792798]
[PMID: 12494873]
[http://dx.doi.org/10.1093/jn/136.7.1935S] [PMID: 16772463]
[http://dx.doi.org/10.1161/01.RES.0000033522.37861.69] [PMID: 12215493]
[http://dx.doi.org/10.1016/j.jacc.2008.06.013] [PMID: 18772060]
[http://dx.doi.org/10.1016/j.ejheart.2005.10.007] [PMID: 16464638]
[http://dx.doi.org/10.1016/j.regpep.2004.10.019] [PMID: 15664671]
[http://dx.doi.org/10.1016/j.neuroscience.2013.07.065] [PMID: 23933309]
[http://dx.doi.org/10.3892/mmr.2015.4691] [PMID: 26676468]
[http://dx.doi.org/10.5937/jomb0-27554] [PMID: 33312067]
[http://dx.doi.org/10.1016/j.cellsig.2004.09.018] [PMID: 15601620]
[http://dx.doi.org/10.1016/j.pharmthera.2005.04.001] [PMID: 15907343]
[http://dx.doi.org/10.1016/S0167-4889(00)00143-9] [PMID: 11336787]
[http://dx.doi.org/10.1159/000493653] [PMID: 30235451]
[http://dx.doi.org/10.1016/j.cca.2015.09.029] [PMID: 26436483]
[http://dx.doi.org/10.1016/j.regpep.2003.11.002] [PMID: 15003827]
[http://dx.doi.org/10.1378/chest.14-1426] [PMID: 25375801]
[http://dx.doi.org/10.1016/j.surg.2015.01.011] [PMID: 25817096]
[http://dx.doi.org/10.1164/rccm.200909-1361OC] [PMID: 20622042]
[http://dx.doi.org/10.1016/j.rmed.2012.10.026] [PMID: 23199840]
[http://dx.doi.org/10.1111/ijlh.13288] [PMID: 32779838]
[http://dx.doi.org/10.1111/jth.14859] [PMID: 32306492]
[http://dx.doi.org/10.1016/j.hrtlng.2020.10.005] [PMID: 33097297]